Patents by Inventor Chad A. Van Huis

Chad A. Van Huis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
    Patent number: 10532088
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 14, 2020
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 10377768
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 13, 2019
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Benzenesulfonamido and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 10189777
    Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: January 29, 2019
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor, Chad A. Van Huis
  • Indazole guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9920012
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: March 20, 2018
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
    Publication number: 20170190659
    Abstract: The invention provides benzenesulfonamido and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such benzenesulfonamido and related compounds.
    Type: Application
    Filed: May 5, 2015
    Publication date: July 6, 2017
    Inventors: Thomas D. Aicher, Donald J. Skalitzky, Clarke B. Taylor, Chad A. Van Huis
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9657033
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 23, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Saturated acyl guanidine for inhibition of FF-ATPase
    Patent number: 9580391
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
    Publication number: 20170007686
    Abstract: The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR?) and provides adoptive cellular therapies using an agonist of ROR?, populations of lymphocyte cells that have been exposed to an agonist of ROR?, populations of dendritic cells that have been exposed to an agonist of ROR?, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR? to a patient.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 12, 2017
    Inventors: Gary D. Glick, Peter L. Toogood, Xiao Hu, Thomas D. Aicher, Laura Lee Celeste, Xikui Liu, Clarke B. Taylor, Chad A. Van Huis
  • N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9512111
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 6, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur G. Romero, Chad A. Van Huis, Thomas D. Aicher, Carl Kaub, Matthew N. Mattson, William D. Thomas, Karin A. Stein, Erik Krogh-Jespersen, Zhan Wang
  • Pyridonyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9370507
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 21, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 9266827
    Abstract: The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: February 23, 2016
    Assignees: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Thomas D. Aicher, Kenneth Jay Barr, Vladimir Simov, William D. Thomas, Peter L. Toogood, Chad A. Van Huis
  • PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20150335625
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: April 1, 2015
    Publication date: November 26, 2015
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • Cycloalkyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9169199
    Abstract: The invention provides cycloalkyl guanidine compounds that inhibit F1F0-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: October 27, 2015
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Pyrazolyl guanidine FF-atpase inhibitors and therapeutic uses thereof
    Patent number: 9139532
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 22, 2015
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. Van Huis
  • INDAZOLE GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20150152063
    Abstract: The invention provides indazole guanidine compounds that inhibit F1F0-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: June 7, 2013
    Publication date: June 4, 2015
    Inventors: Alexander R. Hurd, Donald J. Skalitzky, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20150126493
    Abstract: The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 7, 2015
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Vladimir Simov, Willam D. Thomas, Peter L. Toogood, Chad A. Van Huis
  • SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE
    Publication number: 20150119439
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: June 7, 2013
    Publication date: April 30, 2015
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20150111877
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 23, 2015
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Valdimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Pyridonyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9000014
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: April 7, 2015
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20140088094
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Application
    Filed: November 8, 2011
    Publication date: March 27, 2014
    Applicants: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur Glenn Romero, Chad A. Van Huis, Thomas Daniel Aicher, Carl Kaub, Matthew N. Mattson, William David Thomas, Karin Ann Sttein, Erik Krogh-Jespersen, Zhan Wang